Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 22, 2018 01:00 ET | Source: Novartis Pharma AG

Novartis completes tender offer for Advanced Accelerator Applications S.A. and announces commencement of subsequent offering period

Transaction expands Novartis Oncology neuroendocrine tumor (NET) treatment portfolio and adds radiopharmaceutical technology platform Lutathera® (lutetium Lu 177 dotatate), with a US PDUFA date...
January 18, 2018 05:30 ET | Source: Novartis Pharma AG

Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars

Collaboration aims to help patients worldwide gain access to a range of high-quality, affordable immunology and oncology biologics Partnership will be an important part of Sandoz and Biocon...
January 17, 2018 01:15 ET | Source: Novartis Pharma AG

Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL

Filing acceptance marks second Priority Review granted to Kymriah by the FDA for two distinct indications, underscoring the potential of first ever FDA-approved CAR-T therapy EMA granted...
January 16, 2018 01:15 ET | Source: Novartis Pharma AG

Novartis new data reinforces superiority of Cosentyx® versus Stelara®* in achieving skin clearance for psoriasis patients

Results from CLARITY study show Cosentyx® (secukinumab) was significantly more effective than Stelara®* (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks[1] ...
January 16, 2018 01:00 ET | Source: Novartis Pharma AG

Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA

Adalimumab is an anti-TNF medicine used to treat a range of immunological diseases[1] The comprehensive data package provided is expected to demonstrate that Sandoz proposed biosimilar adalimumab...
January 11, 2018 01:00 ET | Source: Novartis Pharma AG

Novartis appoints Elizabeth Barrett as Oncology Head

Novartis appoints experienced pharmaceuticals industry leader with strong marketing skills to drive oncology business further Novartis appoints ad interim leader for its Global Drug Development...
January 11, 2018 01:00 ET | Source: Novartis Pharma AG

Novartis ernennt Elizabeth Barrett zur Chefin Onkologie

Novartis ernennt eine erfahrene Pharma-Führungskraft mit starken Marketingfähigkeiten, um das Onkologiegeschäft weiter zu entwickeln Novartis ernennt ad interim Leiter für die Global Drug...
January 09, 2018 01:15 ET | Source: Novartis Pharma AG

Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**

SURPASS is the first head-to-head superiority trial versus proposed biosimilar adalimumab** in ankylosing spondylitis (AS)[1] EXCEED is the first head-to-head superiority trial versus Humira®*...
January 04, 2018 01:15 ET | Source: Novartis Pharma AG

Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)

Data supporting designation showed over half of treatment-naïve SAA patients achieved complete response with Promacta when given with standard immunosuppressive therapy, with overall response...
January 03, 2018 01:15 ET | Source: Novartis Pharma AG

Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer

Designation based on Phase III MONALEESA-7 results demonstrating superior efficacy of Kisqali in combination with oral endocrine therapy compared to oral endocrine therapy in pre- or...